Drugmakers increase cashable assets amid unpredictable market factors

Published: 2013-06-13 07:00:00

Updated: 2013-06-13 07:00:00

Korea’s pharmaceutical firms are choosing to hold more of their earnings in cashable assets as they find it harder to invest amid growing market uncertainties and global economic slump.

Cashable assets include cash, cash equivalents and other short-term financial products with a maturity of le...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK